Double-Punch immunotherapy trial aims to wipe out tumors before esophageal cancer surgery
NCT ID NCT04929392
Summary
This study is testing whether a powerful combination of treatments can shrink or eliminate tumors before surgery for esophageal and gastroesophageal junction cancers. Patients receive standard chemotherapy and radiation alongside an immunotherapy drug (pembrolizumab), followed by a second drug (lenvatinib). The main goal is to see if this approach can completely destroy the cancer cells before an operation is needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.